Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

This article was originally published in PharmAsia News

Executive Summary

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China
Advertisement

Related Content

Takeda Buys Out Chinese Venture, Gains Flexibility In Decision-making For Commercial Expansion
What's The Winning Strategy In China? Franchises Are Key
Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%
Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%
Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems
Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death
Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China
Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses
Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Advertisement
UsernamePublicRestriction

Register

SC070598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel